0
0
A new, once-a-week pill developed by MIT researchers could significantly improve the lives of people living with schizophrenia, offering a simpler, more reliable way to manage the condition compared to daily medication regimens.
Published results from a phase 3 clinical trial conducted by MIT spinout Lyndra Therapeutics and published in Lancet Psychiatry reveal that the innovative capsule maintains consistent levels of the antipsychotic drug risperidone in patients’ bodies over the course of a week. The study found that symptom control was just as effective as with daily doses, while also reducing the burden of frequent medication schedules.
How It Works
The capsule, about the size of a multivitamin, is designed to expand into a six-armed star shape after being swallowed. This unique design helps the device remain in the stomach for up to a week, gradually releasing the medication as it dissolves. Once fully expanded, the device becomes too large to pass through the stomach’s exit, ensuring that the drug is delivered consistently throughout the week.
Addressing a Critical Need
Schizophrenia and other chronic psychiatric conditions often require patients to take medication daily, which can be challenging—especially for those whose illness impairs memory or motivation. Inconsistent medication adherence can lead to symptom relapse and increased risk of hospitalization.
“Having the option to take medication by mouth once a week represents an important option that can assist with adherence for the many patients who would prefer oral medications versus injectable formulations,” said study co-author Dr. Leslie Citrome.
Clinical Trial Results
The trial involved 83 patients with schizophrenia or schizoaffective disorder from five sites across the United States. Participants were first given daily risperidone for a week, then switched to the weekly capsule for five weeks. Researchers found that the weekly pill maintained stable drug levels and controlled symptoms effectively, with less variation than daily dosing.
Broader Implications
The technology behind the capsule is not limited to schizophrenia. Researchers believe it could be adapted for other medications, potentially benefiting patients with hypertension, asthma, and other chronic conditions requiring daily medication.
Looking Ahead
While the results are promising, further research and regulatory review will be required before the weekly pill becomes widely available. If approved, it could revolutionize the treatment of schizophrenia and other chronic illnesses, making medication management easier and more effective for millions of patients worldwide.
Disclaimer:
This news article is based on current research findings and clinical trial results as reported by MIT and published in Lancet Psychiatry. The information provided is for informational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional before making changes to medication or treatment plans. The technology described is still under investigation and not yet widely available for clinical use.
